These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 38541099)

  • 1. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice.
    Popa LG; Giurcaneanu C; Portelli MG; Mihai MM; Beiu C; Orzan OA; Ion A; Anghel TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541099
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
    Nikolaou V; Sibaud V; Fattore D; Sollena P; Ortiz-Brugués A; Giacchero D; Romano MC; Riganti J; Lallas K; Peris K; Voudouri D; Lallas A; Fabbrocini G; Lazaridou E; Carrera C; Annunziata MC; Rossi E; Patri A; Rigopoulos D; Stratigos AJ; Apalla Z
    J Am Acad Dermatol; 2021 May; 84(5):1310-1320. PubMed ID: 33279646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psoriasis and psoriatic arthritis following use of dostarlimab for endometrial cancer.
    Goel AR; Sylvester C; Avidan OR; Gilvaz VJ
    BMJ Case Rep; 2024 Aug; 17(8):. PubMed ID: 39097324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.
    Yu Y; Zhou Y; Zhang X; Tan K; Zheng J; Li J; Cui H
    Front Oncol; 2022; 12():934093. PubMed ID: 35912183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
    Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
    Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor-Induced Psoriasis: Diagnosis, Management, and a Review of Cases.
    Pach JJ; Mbonu N; Bhullar S; Cohen JM; Leventhal JS
    Dermatol Clin; 2024 Jul; 42(3):481-493. PubMed ID: 38796277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series.
    Li YJ; Msaouel P; Campbell M; Hwu P; Diab A; Kim ST
    RMD Open; 2024 Aug; 10(3):. PubMed ID: 39214611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis de novo or exacerbation by PD-1 checkpoint inhibitors.
    Wan Z; Huang J; Ou X; Lou S; Wan J; Shen Z
    An Bras Dermatol; 2024; 99(3):425-432. PubMed ID: 38388337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
    Seervai RNH; Heberton M; Cho WC; Gill P; Murphy MB; Aung PP; Nagarajan P; Torres-Cabala CA; Patel AB; Ruiz-Bañobre J; Om A; Yamamoto T; Nikolaou V; Curry JL
    J Cutan Pathol; 2022 May; 49(5):472-481. PubMed ID: 34888886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors.
    Cutroneo P; Ingrasciotta Y; Isgrò V; Rullo EV; Berretta M; Fiorica F; Trifirò G; Guarneri C
    Dermatol Ther; 2021 Mar; 34(2):e14830. PubMed ID: 33527643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of epidermal Langerhans cells in psoriasiform lesions of de novo induced or worsened pre-existing psoriasis following uses of immune checkpoint inhibitors.
    Kase M; Fujita Y; Ota A; Shimizu S; Itoi-Ochi S; Sano S
    J Dermatol; 2022 Sep; 49(9):916-920. PubMed ID: 35545886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.
    Efuni E; Cytryn S; Boland P; Niewold TB; Pavlick A; Weber J; Sandigursky S
    J Clin Rheumatol; 2021 Oct; 27(7):267-271. PubMed ID: 31977647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psoriasis in the Era of Targeted Cancer Therapeutics: A Systematic Review on De Novo and Pre-existing Psoriasis in Oncologic Patients Treated with Emerging Anti-neoplastic Agents.
    Madan V; Ortiz-López LI; Sakunchotpanit G; Chen R; Nayudu K; Nambudiri VE
    Dermatol Ther (Heidelb); 2024 Jul; 14(7):1755-1766. PubMed ID: 38907875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultraviolet Phototherapy Management of Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(27):1-66. PubMed ID: 23074532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of diabetes mellitus in patients treated with immune checkpoint inhibitors (ICI) therapy - A comprehensive cancer center experience.
    Zhang Z; Sharma R; Hamad L; Riebandt G; Attwood K
    Diabetes Res Clin Pract; 2023 Aug; 202():110776. PubMed ID: 37311494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of inverse psoriasis subtype with immune checkpoint inhibitors.
    Jfri A; Leung B; Said JT; Semenov Y; LeBoeuf NR
    Immunother Adv; 2022; 2(1):ltac016. PubMed ID: 36196370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
    Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
    Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.